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Abstract
Background: Combined hepatocellular-cholangiocarcinoma (cHCC-CC) is an uncommon primary liver malignancy
and little known about the clinical and imaging characteristics of cHCC-CC. We aim to define the demographics,
imaging features of cHCC-CC on contrast-enhanced ultrasound (CEUS) and contrast-enhanced computed
tomography (CT) in this study.
Methods: From January 2005 to December 2014, 45 patients with pathologically proven cHCC-CC who underwent
preoperative CEUS and 43 patients who had additional CT scan in our institution were included. A retrospective review
of the imaging studies and clinical data in these patients was conducted.
Results: In our series, cHCC-CC accounted for 1.6 % of all primary liver malignancy. Mean age of patient with
cHCC-CC was 52.8 year (range: 28–74 year) and 88.9 % (40/45) of patients were male. Thirty of forty five patients
(66.7 %) had cirrhosis and 20 % (9/45) of patients had chronic hepatitis B without cirrhosis. Alpha–fetoprotein (AFP) was
elevated in 62.2 % (28/45) of patients and carbohydrate antigen 19–9 (CA19-9) elevated in 22.2 % (10/45) of patients).
Both AFP and CA19-9 were simultaneously elevated in 15.6 % (7/45) of patients. Enhancement pattern resembling
cholangiocarcinoma (CC) was noted in 53.3 % (24/45) of patients (on CEUS and in 30.2 % (13/43) of patients at CT.
Enhancement pattern resembling hepatocellular carcinoma (HCC) was observed in 42.2 % (19/45) of patients
on CEUS and in 58.1 % (25/43) of patients at CT. The percentage of tumors showing CC enhancement pattern
(27.9 %, 12/43) was comparable with that of tumors showing HCC enhancement pattern (44.2 %, 19/43) on both CEUS
and CT (p = 0.116).
Simultaneous elevation of tumor markers (AFP and CA19-9) or tumor marker elevation (AFP or CA19-9) in discordance
with enhancement pattern on CEUS was demonstrated in 51.1 % (23/45) of patients and on CT in 53.5 %
(23/43) of patients, which was significantly more than simultaneous elevation of tumor markers (AFP and
CA19-9) alone (p = 0.000).
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Conclusions: The clinical characteristics of cHCC-CC are similar to those of HCC. The cHCC-CC tumors display
enhancement patterns resembling CC or HCC in comparable proportion on both CEUS and CT. Combination
of simultaneous elevation of tumor makers (AFP and CA19-9) and tumor mark elevation (AFP or CA19-9) in
discordance with presumptive imaging findings on CEUS or CT may lead significantly more patients to be
suspicious of the diagnosis of cHCC-CC.
Keywords: Combined hepatocellular-cholangiocarcinoma, Contrast-enhanced ultrasound, Computed
tomography, Alpha-fetoprotein, Carbohydrate antigen 19–9
Background
Combined hepatocelluar - cholangiocarcinomas (cHCC-
CC) are uncommon form of primary hepatic carcinoma,
accounts for 1.0–6.3 % of all primary liver cancers in
Asia and 2.4–14.2 % of all primary liver cancers in
Western countries [1, 2]. It was first defined by Allen
and Lisa [3] and has been divided into three types of
cHCC–CC. Type A is termed “double cancer” and rep-
resents cases in which hepatocelluar carcinoma (HCC)
and cholangiocarcinomas (CC) exist separately. Type B,
which is called the combined type, is defined as cases in
which HCC and CC locates contiguously but independ-
ently. The type C, which is referred to as the mixed type,
occurs when HCC and CC components intermingle
within the same tumor. Only Allen and Lisa type C
tumors involved a mixture of both hepatocellular and
biliary epithelial cell differentiation, appear to be true
biphenotypic cHCC-CC. It is postulated that evolution
of cHCC–CC tumors from common hepatic progenitor
cells may account for the biphenotypic features of these
tumors [4–8]. Due to the relative rarity of this tumor
type, little is known about the risk factors, imaging ap-
pearance, or prognosis. Few studies have demonstrated
risk factors that overlap with hepatocellular carcinoma
(HCC) and cholangiocarcinoma (CC), though not all ap-
pear to arise in the background of cirrhosis [9]. The clin-
ical characteristics of cHCC-CC were similar to those of
HCC [10], but overall survival was more similar to or
poorer than that of CC [2, 10]. Survival may be related
to tumor biology rather than the cause. Multimodal
treatment with an initial aggressive therapeutic approach
can improve survival [10]. Given the overlap in patient
demographics and the unique nature of cHCC-CC, pre-
operative diagnosis is crucial for appropriate manage-
ment. Few studies have evaluated the radiological
characteristics of cHCC-CC on computed tomography
(CT) or magnetic resonance imaging (MRI) with limited
number of patients [11–15]. The presence of imaging
features of both HCC and CC in the same tumor may
alert the radiologist to the possibility of cHCC-CC
though which occurred in the minority of cases [9, 15].
To our knowledge, no study has reported the imaging
features of cHCC-CC on contrast-enhanced ultrasound
(CEUS) up to now. The main tumor markers of interest
are carbohydrate antigen 19–9(CA19-9) and α -fetopro-
tein (AFP), which are useful adjuncts to imaging in pa-
tients with CC and HCC respectively [16]. Simultaneous
elevation of both CA 19–9 and AFP has been suggested
as highly concerning for cHCC-CC tumors [17]. Other
reports suggest that discordance between serum tumor
marker elevation and imaging morphology may be sug-
gestive [18]. However, these results were based on clin-
ical data from very limited number of patients and the
imaging features of CEUS not included. Therefore, the
purpose of this study was to retrospectively evaluate
the demographics, clinical presentation, and imaging
features on CT and CEUS in patients with cHCC-CC
tumors, in the hope of defining features of the un-
common malignant hepatic tumor that may improve
preoperative diagnosis and better guide clinical man-
agement decisions.
Methods
Patient population and clinical information
Institutional review board approval for this study was
obtained from the ethics committee of Southwest hos-
pital. The need for informed consent of patient was
waived by the ethics committee of Southwest hospital in
this retrospective study. From January 2005 to December
2014, pathology databases of our hospital recorded 2863
patients with primary liver cancer, including 46 patients
with mixed type (biphenotypic) of cHCC-CC which
accounted for 1.6 % of all primary liver cancer. One
case of cHCC-CC without available CEUS imaging
was excluded from the present study. Patients with
available cross sectional imaging were included in the
study. Clinical information was retrospectively found
from our hospital information system. Serum tumor
markers reported were drawn before treatment and
within 1 week of the imaging examination. Normal
values were 0–20 ng/ml for AFP and 0-22U/ml for
CA19-9 in our hospital. Cirrhosis was confirmed
histopathologically through examination of resected
liver specimen.
All the 45 tumors were excised and underwent tissue
diagnosis of the surgical specimen. Liver sections were
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examined by pathologists with over 20 year experience
of liver pathology (XCY and DYG). The final diagnosis
of biphenotypic primary liver carcinoma (both types
of tumor intermixed) depended on a combination of
H and E stain findings [19] and proof of both hepa-
tocellular (polyclonal arcinoembryonic antigen, a marker
of canalicular formation,) and biliary differentiation
(keratin 7 or keratin19) immunohistochemical markers.
Sub-classification was done according o the 2010
World Health Organization Tumors of the Digestive
System classification [20]. In patient with more than
one lesion,the pathological diagnosis of the largest
one was confirmed biphenotypic cHCC-CC. Another 3
patients with double cancer (HCC and CC exist separ-
ately) and 7 patients with combined tumors (both types
of tumor contiguous to each other) were excluded from
the present study.
We performed a per-patient analysis. In a patient
with more than one solid lesion in the liver, only the
largest one was measured and investigated because
CEUS could not scan multiple nodules simultan-
eously after one injection of contrast agent if the
nodules are not at the same scan plane and it is
difficult to correspond the pathology of each tumor
to the imaging of US in patients with multiple hep-
atic lesions.
US scan
US examinations were performed by two experienced
physicians with over 16 years of experience of liver
ultrasound examination (R L, and XH Z) with an
Acuson Sequoia 512 ultrasound unit (Siemens Medical
Solutions, Santa Clara, Calif ). Baseline US was per-
formed with a multifrequency 4C1 convex array probe.
The gray-scale US characteristics of the lesion, includ-
ing location, size, shape, and echogenicity were re-
corded. CEUS was performed by using contrast pulse
sequencing (CPS) imaging. Real-time contrast imaging
setting was used with a low mechanical index of <0.2
and a volume of 2.4 mL of blood pool contrast agent
(SonoVue, Bracco Imaging B.V, Geneva, Switzerland)
was injected into cubital vein in bolus via a 20-gauge
needle followed by a 5 mL saline flush. After contrast
medium injection, hepatic lesion was scanned con-
tinuously for up to 4 min. The whole vascular phase
was studied, consisting of the arterial phase (0–30 s
from beginning of contrast agent bolus injection), por-
tal phase (31–120 s after the injection), and delayed
phase (121–240 s after the injection) according to
EFSUMB recommendations [21]. All ultrasound im-
ages of cHCC-CC tumors were reviewed retrospect-
ively for this study by two physicians (R L, and XH Z)
in consensus.
CEUS image analysis
The contrast vascular patterns on CEUS were defined by
comparing the enhancement behaviour of the tumor
with the surrounding liver parenchyma and classified as:
(1) Peripheral hyperenhancement—irregular rim-like
hyperenhancement at the peripheral part of the
lesion with sparse filiform and punctiform internal
enhancement.
(2) Heterogeneous hyperenhancement—when
the lesion displays mixed hyperenhancement
inhomogeneously at both the periphery and the
central part of the lesion.
(3) Homogeneous hyperenhancement—when the whole
lesion shows hyperenhancement homogeneously.
(4) Hypoenhancement—the lesion enhances in the
less degree than that of the surrounding liver
parenchyma.
(5) Isoenhancement—the lesion enhances in the similar
degree as the surrounding liver parenchyma.
(6) Non-enhancement—no appearance of contrast
agent (microbubbles) at both the periphery and the
central part of the lesion.
Wash-out appearance was considered as the presence
of hypoenhacement of the lesion in the portal or late
phases preceded by hyperenhancement in the arterial
phase. A lesion lacking any enhancement in all phases
was not defined as washout. When a nodule shows het-
erogeneous hyperenhancement in the arterial phase, ob-
servation of washout was confined to the area showing
hyperenhancement in the arterial phase, and the area
showing non-enhancement was excluded from the ob-
servation. The extent of washout was classified as:
(1) Marked washout—when the lesion displays
obviously lower echogenicity than the surrounding
liver parenchyma in the portal or late phases
preceded by hyperenhancement in the arterial phase.
(2) Mild washout —when the lesion shows slightly
lower echogenicity than the surrounding liver
parenchyma in the portal or late phases preceded
by hyperenhancement in the arterial phase.
(3) No washout—when the lesion enhances in the
similar degree or higher degree as the surrounding
liver parenchyma in the portal or late phases
preceded by hyperenhancement in the arterial phase.
Typical HCC pattern on CEUS was defined as hyper-
enhancement in the arterial phase followed by slow or
slight washout in the portal or late phase,and the wash
out tends to start later in HCC, usually not before 60 s
after injection [22, 23]. On the contrary, most peripheral
cholangiocarcinoma showed wash out emergence before
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60 s and marked wash out in the portal phase on CEUS
[24, 25]. Typical CC pattern on CEUS was defined as:
(1) Peripheral arterial rim enhancement followed by
marked washout in the portal phase; (2) Arterial hyper-
enhancement followed by quick (washout begins before
60 s after contrast agent injection) and marked washout
in the portal phase [22, 24, 25].
CT scan
Abdomen CT was performed with multidetector-row
CT (MDCT, 64 detector rows, Definition, Siemens,
Erlangen, Germany) using a 4 phase contras-enhanced
protocol (unenhanced, hepatic arterial, portal venous,
and delayed phases). First, an unenhanced scan was ob-
tained through the liver. Next, after intravenous infusion
of 2 ml /kg of a nonionic iodine-containing contrast
agent (ultravist 370, Scherning AG, Berlin, Germany)
using a power injector (Stellant CT Injection System,
Medrad, Indianola, Pennsylvania) at a rate of 4.0 ml/s,
contrast-enhanced scans were obtained in arterial with
bolus test trigger for optimal characterization of focal
hepatic lesions. Data acquisitions were obtained through
the whole liver in a craniocaudal direction during a sin-
gle breath-hold helical acquisition for 4–6 s with 5 mm
slice thickness and 0.5 s rotation time. The acquisition
of the arterial phase was automatically started 5 s after
contrast agent reaching the threshold in the aorta. The
start of acquisition sequences was 60 s for the portal
venous phase and 180 s for the delayed phase.
Categorization of enhancement patterns at CT
The enhancement through each of the different phases
after intravenous contrast administration was registered
as follows: (1) globally hyperdense: increased signal rela-
tive to the surrounding liver parenchyma, involving the
totality of the lesion; (2) partially hyperdense: increased
signal involving more than 50 % of the lesion cross-
section area with a non-homogeneous distribution; (3)
peripherally hyperdense: increased signal limited to the
periphery of the lesion, involving less than 25 % of its
area, resembling a rim-like pattern; (4) isodense: same
density as the surrounding liver parenchyma; (5) hypo-
dense: lower density compared to the liver parenchyma
involving more than half of the cross-sectional area of
the tumor. Dynamic pattern of enhancement was de-
fined according to the analysis of the progression of
contrast enhancement over different phases of the study,
as follows: (1) stable or persistent contrast enhancement:
the nodule enhancement is unmodified from the arterial
to the portal venous and delayed phases; (2) progressive
contrast enhancement: the nodule enhances progres-
sively over time, reaching maximal intensity in delayed
phases; (3) ‘wash-out’ pattern: global intense/partial
hyperdense of the lesion during the arterial phase
followed by hypodense in portal and/or delayed venous
phases; (4) all other cases. This classification was
adopted from Rimola et al. [26] and lavarone et al. [27].
CT findings were evaluated in consensus by 2 abdom-
inal radiologists (PC and SYD) with over 15 years of
experience in liver radiology who were blinded to CEUS
findings and pathological results of the tumors. Typical
HCC pattern on CT was defined as hyperenhancement
in the arterial phase followed by washout in the portal
or late phase of the nodule [28]. Typical CC pattern on
CT was defined as progressive centripetal enhancement
or stable persistent enhancement of the nodule [27].
Statistical analysis
We performed a per-patient analysis in this study. Char-
acteristics of the patients are expressed as median and
range or count and proportion. Comparison of CEUS
and CT was done by using the chi-squared test for
categorical variables. A P value of less than 0.05 was
considered statistically significant. Statistical analysis was




Demographics of 45 patients with cHCC-CC are shown
in Table 1. Mean age of patients was 52.8 year (range:
28–74 year) and 40 patients were male (88.9 %). Thirty
patients (66.7 %) had cirrhosis. The etiology of cirrhosis
was viral hepatitis B infection in 24 patients, combin-
ation of viral hepatitis B infection and alcohol misuse in
5 patients. Nine patients had chronic hepatitis B without
cirrhosis (20 %). Of the 45 patients with cHCC-CC
tumors, 6 presented incidentally, 10 discovered on cir-
rhosis screening, 22 presented with abdominal pain, 2
with jaundice, 2 with tarry stool, 1 with edema of lower
limbs. Of the 22 patients presented with abdominal pain,
4 patients had a palpable mass. In two patients, the pres-
entation is unknown. All the 45 patients had AFP assay
which was abnormally elevated in 28 patients (62.2 %)
and normal in 17 patients. Forty three patients had
serum assays of carcinoembryonic antigen (CEA) which
was elevated in 5 patients (11.6 %) and normal in 38 pa-
tients. Forty two patients had serum assays of CA-125
which was elevated in 6 patients (14.3 %) and normal in
36 patients. Forty five patients had serum assays of
CA19-9 which was elevated in 10 patients (22.2 %) and
normal in 35 patients. Both AFP and CA19-9 were sim-
ultaneously elevated in 7 patients (15.6 %). The average
size of cHCC-CC was 5.3 cm and over half of them were
less than 5 cm. Most patients had single tumor and over
half of them were located in the right lobe of liver. In 6
patients with 2 hepatic nodules, pathological diagnosis
of all the nodules was cHCC-CC. In 1 patient with 4
Li et al. BMC Cancer  (2016) 16:158 Page 4 of 11
hepatic nodules, pathological diagnosis of 3 nodules, in-
cluding the largest one was cHCC-CC, and 1noule was
heamangioma.
Radiological features
The enhancement appearances of cHCC-CC on CEUS
in 45 patients are shown in Table 2. Tumors showing
peripheral hyperenhancement in the arterial phase
followed by marked washout in the portal phase in 9
patients were defined as CC pattern. Tumors showing
heterogeneous (8 tumors) or homogeneous (7 tumors)
hyperenhancement in the arterial phase followed by
early (washout begins earlier than 60 s) and marked
wash out during the portal phase were judged as CC
pattern. Tumors showing heterogeneous (13 tumors) or
homogeneous (6 tumors) hyperenhancement in the ar-
terial phase followed by both slow (washout begins later
than 60 s) and mild wash out in the portal or late phase
were judged as HCC pattern. The enhancement pattern
of 2 patients was judged as indeterminate because one
tumor showed heterogeneous hyperenhancemen in the
arterial phase followed by isoenhancement in the portal
and the late phase, and another tumor displayed hypoen-
hancement in the arterial phase, remained hypoenhance-
ment in the portal and the late phase. The average time
of washout emergence on CEUS was 58.18 s (median
:53 s, range :22 s ~ 129 s). The percentage of tumors
showing CC enhancement pattern (53.3 %) was similar
Table 1 Demographics of 45 patients with combined hepatocellular-cholangiocarcinoma
Number (%) Mean ± SD Median (range)
Age (year) 52.8 ± 10.4 51.5 (28–74)
Male/female 40/5
AFP (ng/ml) 680.8 ± 1700.2 68.6 (1.02–9675)
≤ 20 17 (37.8)
21–200 15 (33.3)
> 200 13 (28.9)
Underling liver disease
Cirrhosis 30 (66.7)
Chronic hepatitis B 4 (8.9)
Chronic hepatitis C
Alcoholic 3 (6.7)
Chronic hepatitis B and alcoholic 5 (11.1)
No evidence of chronic liver disease 3 (6.7)
Nodule size (cm) 5.3 ± 3.2 4.5 (1.5–13.8)
< 5 cm 24 (53.3)
5–10 cm 15 (33.3)




More than three 1 (2.2)
Location of nodules
Left lobe 8 (17.8)
Right lobe 31 (68.9)
Both left and right lobe 3 (6.7)
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to that of tumors showing HCC enhancement pattern
(42.2 %) on CEUS (p = 0.291).
Forty three patients had unenhanced CT scan. Forty of
the tumors were hypodense and 3 were hyperdense. Hep-
atic capsular retraction was revealed in 4 cases (9.3 %).
Three patients had intrahepatic biliary dilatation (7.0 %).
Five patients had malignant portal veins thrombus
(11.6 %) and 5 had regional lymphadenopathy (11.6 %).
Intrahepatic metastasis was observed in 7 patients (16.3 %).
Enhancement appearances of cHCC-CC on contrast-
enhanced CT in 43 patients are shown in Table 3. Tumors
showing stable persistent peripherally hyperenhancement
from the arterial phase to the late phase in 8 patients were
defined as CC pattern. Tumors showing progressive
delayed enhancement from the arterial phase to the late
phase in 5 patients were also judged as CC pattern.
Tumors showing hyperenhancement (24 heterogeneous, 1
homogeneous) in the arterial phase followed by washout in
the portal or the late phase in 25 patients were defined as
HCC pattern. Tumors showing hypoenhancement from
the arterial phase to the late phase in 4 patients and 1
tumor showing hyperenhancement in the arterial phase
and the portal phase followed by isoenhancement in the
late phase were judged as indeterminate pattern. The per-
centage of tumors showing CC enhancement pattern
(30.2 %) was less than that of tumors showing HCC en-
hancement pattern (58.1 %) on CT (p = 0.009). Twelve of
forty three patients displayed CC enhancement pattern on
both CEUS and CT (27.9 %), while 44.2 % (19/43) of pa-
tients demonstrated HCC enhancement pattern at both
CEUS and CT. The percentage of tumors showing CC en-
hancement pattern was comparable with that of tumors
showing HCC enhancement pattern (p = 0.116).
Correlations of AFP and CA19-9 levels with enhancement
patterns on CEUS and CT
In 7 patients with simultaneous elevation of both AFP
and CA19-9, CC enhancement pattern was observed in
5 patients on CEUS and 1 patient at CT. HCC enhance-
ment pattern was noted in 2 patients on CEUS and 6
patients at CT respectively (Fig. 1). Correlations between
AFP test and enhancement patterns of CEUS and CT
Table 2 The enhancement patterns of combined hepatocellular-cholangiocarcinoma on CEUS in 45 patients
Enhancement appearance Number %
Arterial phase
Peripheral hyperenhancement 9 (20.0)
Heterogeneous hyperenhancemen 22 (48.9)





Heterogeneous hyperenhancement 1 (0.2)
Homogeneous hyperenhancement 0 (0)
Slight hypoenhancement 17 (37.8)




Heterogeneous hyperenhancement 1 (0.2)
Homogeneous hyperenhancement
Slight hypoenhancement 8 (17.8)
Marked hypoenhancement 35 (77.8)
Isoenhancement 1 (0.2)
Emergence of-washout
< 60 seconds 28 (62.2)
60–120 seconds 13 (28.9)
> 120 seconds 2 (4.4)
No washout 2 (4.4)
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are shown in Table 4. AFP was elevated and CA19-9
normal in 9 of 45 (20.0 %) patients showing CC
enhancement pattern on CEUS and in 7of 43 (16.3 %)
patients showing CC enhancement pattern on CT (p =
0.651) (Fig. 2). In 3 patients with elevated CA19-9 and
normal AFP, HCC enhancement pattern was noted in 3
patients on CEUS and in 2 patients at CT (Fig. 3),
CC enhancement pattern was observed 1 patient at
CT. Correlations between CA19-9 test and enhance-
ment patterns of CEUS and CT are shown in Table 5.
Elevated tumor markers (AFP or CA19-9) were in
discordance with imaging findings in 19 of 45
(42.2 %) patients on CEUS and in 16 of 43 (37.2 %)
patients at CT (p = 0. 0.631). Simultaneous elevation
of tumor markers (AFP and CA19-9) or tumor marker
elevation (AFP or CA19-9) in discordance with enhance-
ment pattern on CEUS was demonstrated in 26 of 45
patients, which was significantly more than simultaneous
elevation of tumor markers (AFP and CA19-9) alone (7/
45, p = 0.000). Simultaneous elevation of tumor markers
(AFP and CA19-9) or tumor marker elevation (AFP or
CA19-9) in discordance with enhancement pattern on CT
was observed in 23 of 43 patients, which was significantly
more than simultaneous elevation of tumor markers
(AFP and CA19-9) alone (7/43, p = 0.000).
Discussion
Combined hepatocellular-cholangiocarcinoma accounts
for 0.4–14.2 % of all primary liver carcinomas, with not
only local incidence varying considerably between re-
gions [16, 18], but also the different including criteria for
classification in previous literature. Although some pub-
lished reports involving only Allen and Lisa type C of
cHCC-CC [18, 29], others either included all three types
of cHCC-CC [30, 31] or did not state their criteria for
diagnosis and classification [32, 33]. From January 2005
to December 2014, 46 out of 2863 patients underwent
surgery or biopsy for hepatic malignancy at our hospital
had unequivocal mixed type (biphenotypic) of cHCC-
CC. The incidence of this real mixed type cHCC-CC
composed of cholangiocyte-derived and hepatocyte-
derived neoplastic elements is 1.6 %. In the present
series, most patients with cHCC-CC had cirrhosis
(66.7 %) or chronic hepatitis B (20 %). The mean age of
patients was 52.8 year and 88.9 % of patients were male.
Our data demonstrated that cHCC-CC developed more
Fig. 1 cHCC-CC in a patient with chronic hepatitis B. Simultaneous elevation of AFP (718 ng/ml) and CA19-9 (45.0U/ml) was detected in the patient.
Unenhanced ultrasound shows a hypoechoic mass of 4.6 cm in right lobe of the liver (a, arrow). The mass displays heterogeneous hyperenhancement in
the arterial phase (b, 26 s after contrast agent injection) followed by quick (c, 58 s after injection) and marked washout (d, 102 s after injection) in the portal
phase on CEUS, resembling the enhancement pattern of intrahepatic cholangiocarcinoma. Unenhanced CT scan reveals a hypodense mass in right lobe of
the liver (e, arrow). The mass displays heterogeneous hyperenhancemen in the arterial phase (f, arrow) followed by washout (g) in the portal phase and
the late phase (h) on contrast-enhanced CT, resembling the enhancement pattern of HCC
Table 3 Enhancement patterns of combined hepatocellular-









12 (27.9) 13 (30.2) 7 (16.3)
Partially hyperdense No.(%) 24 (55.8) 5 (11.6) 6 (13.9)
Globally hyperdense No.(%) 2 (0.5)
Isodense No.(%) 1 (0.2)
Hypodense No.(%) 5 (11.6) 25 (58.1) 29 (67.4)
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frequently in a middle-aged male population with chronic
hepatitis and cirrhosis mostly related to chronic hepatitis
B, indicating the clinical characteristics of cHCC-CC are
similar to those of HCC [10, 34]. However, this is incon-
sistent with two reports from Western countries [15, 18],
which published data of 27 patients and 29 patients, cir-
rhosis was seen in 0 % and 20 %, positive hepatitis B or C
detected in 15 % and 10 % of the patients respectively.
The discrepancy may relate to different population back-
ground characteristics, reflecting the high rates of hepa-
titis B viral infection in Chinese populations. Although the
majority of patients had insidious onset of cHCC-CC with
late presentation of advanced disease, 35.6 % of our pa-
tients were discovered on cirrhosis screening or presented
incidentally at early stage for regular health examination
by ultrasound.
In our study, 27.9 % of the cases showed arterial periph-
eral hyperenhancement on CT, which is lower than previ-
ous reports by Ebied et al. (50 %) and Fowler et al. (51.9 %)
[13, 15]. On the contrary, 60.5 % of our patients displayed
heterogeneous or homogeneous hyperenhancement in the
arterial phase that is higher than in the study by Ebied et
al. (33.3 %). Patients with cHCC-CC in the present study
demonstrated more HCC enhancement pattern (58.1 %)
and less CC enhancement pattern (30.2 %) than reported
by Fowler et al. (31.0 %, 41.4 % respectively). An explan-
ation of these discrepancies may be the tumor size, which
was much smaller in our study (median size 4.5 cm) as
compared with the data reported by Ebied et al. (median
size 7 cm) and by Fowler et al. (median size 7.5 cm).As the
tumor grows larger, a relatively smaller blood supply is
available, leading to necrosis and more fibrous stroma for-
mation in the central portion of the tumor, which consti-
tute the pathological background of CC enhancement
pattern on contrast-enhanced CT [35]. Capsular retraction
and biliary ductal dilatation have been considered import-
ant ancillary features of CC. Less patients with cHCC-CC
revealed capsular retraction (9.3 %) and biliary ductal dila-
tation (7.0 %) on CT in our data than reported by Ebied et
al. (26.7 %, 16.7 %) and by Fowler et al. (41.4 %, 34.5 %).
We favor to interpret these inconformity in the light of the
differences in tumor size and the underling liver diseases,
namely, the tumors of our patients were much smaller and
more patients had cirrhosis than in the previous series
mentioned above.
Imaging characteristics of cHCC-CC on CEUS has not
been reported up to now. Our study demonstrated that
95.6 % of the tumor showed washout enhancement
pattern on CEUS, indicating a malignant nature of the
tumor. Imaging features of cHCC-CC may display as CC
Table 4 Correlation between AFP test and enhancement
patterns of CEUS and CT
CEUS pattern (n = 45) CT pattern (n = 43)
CC HCC indeterminate CC HCC indeterminate
AFP normal 10 7 5 9 3
AFP elevated 14 12 2 8 16 2
Fig. 2 cHCC-CC in a patient with cirrhosis related to chronic hepatitis B infection. CA19-9 test was normal and AFP elevated (178.5 ng/ml) in
discordance with presumptive imaging findings in the patient. Unenhanced ultrasound shows a hypoechoic nodule (a, arrow) of 2.7 cm in right
lobe of the liver (RL). The nodule demonstrates peripheral rim-like enhancement in the arterial phase (b, 18 s after contrast agent injection, arrow)
followed by quick (c, 37 s after injection) and marked washout (d, 82 s after injection) in the portal phase on CEUS, resembling the enhancement
pattern of intrahepatic cholangiocarcinoma. Unenhanced CT scan reveals a hypodense nodule in right lobe of the liver (e, arrow). The nodule
displays peripheral rim-like enhancement in the arterial phase (f, arrow) followed by stable and persistent peripheral rim-like enhancement in
the portal (g) and the late phase (h, arrow), resembling the enhancement pattern of intrahepatic cholangiocarcinoma
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enhancement pattern or HCC enhancement pattern. The
percentage of the two types of enhancement pattern on
CEUS showed no statistical difference in our series. Our
results demonstrated that imaging features of cHCC-CC
may resemble either CC or HCC.CC enhancement pattern
and HCC enhancement pattern are likely present in a
comparable proportion in patients with cHCC-CC on
CEUS.
Serum tumor markers of potential utility in cHCC-CC
are CA 19–9 and AFP, which are associated with CC
and HCC respectively. When both are simultaneously
elevated or elevated in discordance with presumptive
imaging findings (i.e., elevated CA 19–9 with imaging
findings of HCC pattern, or elevated AFP with imaging
findings of CC pattern), cHCC-CC should at least be
suggested [9, 17]. However, this point of view was based
on few studies with very limited number of patients (less
than 15 patients) [11, 17, 36] and needs to be evaluated
in more patients. In addition, the imaging features of
cHCC-CC on CEUS have not been taken into consider-
ation up to now. Previous reports demonstrated that
elevated serum AFP levels were found in 33 %–78 % and
elevated CA19-9 in 20 %–36 % of patients with cHCC-
CC [11, 17, 36]. In our series, AFP was abnormally ele-
vated in 62.2 % and CA19-9 in 22.2 % of patients, which
is comparable to previous reports. AFP and CA19-9
were simultaneously elevated in 15.6 % of patients in the
present study, indicating a much low sensibility if this
criterion alone was used for suggestion of cHCC-CC. In
our study, simultaneous elevation of tumor markers
(AFP and CA19-9) or tumor marker elevation (AFP or
CA19-9) in discordance with enhancement pattern on
CEUS or on CT was demonstrated in significantly more
patients (51.1 %, 53.3 % respectively) than simultaneous
elevation of tumor markers (AFP and CA19-9) alone
(15.6 %, p = 0.000), indicating that when both the results
of tumor makers and imaging features of CEUS or CT
were taken into consideration, the possibility of cHCC-
CC may be suggested in significantly more patients.
There are some limitations in the present study. First,
it is a retrospective analysis, though the rarity of cHCC-
CC lends itself almost exclusively retrospective design.
Second, the patient population is relatively small, con-
sisting of 45 patients with cHCC-CC out of 2863 cases
of primary liver malignancy. Nevertheless, our sample
size is relatively larger than most previously published
series. Third, only 2 patients in our study had MRI exam-
ination before operation, the imaging features of cHCC-
CC on MRI could not be summarized. This reflects the
fact that in many countries worldwide, with a high
Fig. 3 cHCC-CC in a patient with cirrhosis related to chronic hepatitis B infection. AFP test was normal and CA19-9 elevated (50.3U/ml) in
discordance with presumptive imaging findings in the patient. Unenhanced ultrasound shows a hyperchoic mass of 3.7 cm with hypoechoic
halo (arrow) in right lobe of the liver (a). The mass displays heterogeneous hyperenhancemen in the arterial phase (b, 29 s after contrast agent
injection) followed by slow washout in the portal phase (c, 110 s after injection, arrow) and mild washout (d, 179 s after injection, arrow) in
the late phase on CEUS, resembling the enhancement pattern of HCC. Unenhanced CT scan reveals a hypodense mass in right lobe of the
liver (e, arrow). The mass displays heterogeneous hyperenhancement in the arterial phase (f) and the portal phase (g) followed by washout in
the late phase (h) on contrast-enhanced CT, resembling the enhancement pattern of HCC
Table 5 Correlation between CA19-9 test and enhancement
patterns of CEUS and CT
CEUS pattern (n = 45) CT pattern (n = 43)
CC HCC indeterminate CC HCC indeterminate
CA19-9 normal 19 14 2 11 17 5
CA19-9 elevated 5 5 2 8
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incidence of HCC, the availability of MRI scan for the
diagnosis of focal liver lesions is still much low.
Conclusions
Combined hepatocelluar – cholangiocarcinomas (biphe-
notypic) is an uncommon primary liver malignancy with
background population characteristics similar to HCC.
Imaging features of CC or HCC presents in comparable
proportion in cHCC-CC on both CEUS and CT. Com-
bination of simultaneous elevation of tumor makers
(AFP and CA19-9) and tumor mark elevation in discord-
ance with presumptive imaging findings on CEUS or CT
may lead significantly more patients to be suspicious of
the diagnosis of cHCC-CC.
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